Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients

1

Myelofibrosis patients on JAK inhibitors showed severely impaired immune responses to COVID-19 vaccination compared to healthy controls.
2

Only 6.3% of myelofibrosis patients on JAK inhibitors seroconverted after the first vaccine dose, increasing to 23.5% after the second dose.
3

Healthy controls achieved a median seroconversion ratio of 4.56 after two doses, while myelofibrosis patients on JAK inhibitors had a ratio of 0.40.
4

The frequency of Spike-reactive T cells in myelofibrosis patients post-vaccination was significantly lower than in healthy controls.
5

The study highlights the need for tailored vaccination strategies for myelofibrosis patients receiving JAK inhibitors due to their impaired immune response.

Blood Cancer Journal

by Ahmad Alcheikh, Griffith B. Perkins, Phillippa A. Pucar, Amelia Cecchin, Cheng Sheng Chai, Matthew Tunbridge, Anouschka Akerman, Anupriya Aggarwal, Vanessa Milogiannakis, Stuart Turville, Sharon Allen, Pravin Hissaria, Tatjana Banovic, P. Toby Coates, David M. Ross
April 10, 2023

1